Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.
Institution of Translational Medicine, Lund University, Malmö, Sweden.
Eur Urol. 2024 Nov;86(5):391-399. doi: 10.1016/j.eururo.2024.08.013. Epub 2024 Aug 29.
Grade is an important determinant of progression in non-muscle-invasive bladder cancer. Although the World Health Organization (WHO) 2004/2016 grading system is recommended, other systems such as WHO1973 and WHO1999 are still widely used. Recently, a hybrid (three-tier) system was proposed, separating WHO2004/2016 high grade (HG) into HG/grade 2 (G2) and HG/G3 while maintaining low grade. We assessed the prognostic performance of HG/G3 and HG/G2. Three independent cohorts with 9712 primary (first diagnosis) Ta-T1 bladder tumors were analyzed. Time to progression was analyzed with cumulative incidence functions and Cox regression models. Harrell's C-index was used to assess discrimination. Time to progression was significantly shorter for HG/G3 than for HG/G2 in multivariable analyses (cohort 1: hazard ratio [HR] = 1.92; cohort 2: HR = 2.51, and cohort 3: HR = 1.69). Corresponding progression risks at 5 yr were 18%, 20%, and 18% for HG/G3 versus 7.3%, 7.5%, and 9.3% for HG/G2, respectively. Cox models using hybrid grade performed better than models with WHO2004/2016 (all cohorts; p < 0.001). For the three cohorts, C-indices for WHO2004/2016 were 0.69, 0.62, and 0.75, while, for hybrid grade, C-indices were 0.74, 0.68, and 0.78, respectively. Subdividing the HG category into HG/G2 and HG/G3 stratifies time to progression and supports the recommendation to adopt the hybrid grading system for Ta/T1 bladder cancers.
分级是非肌肉浸润性膀胱癌进展的重要决定因素。尽管世界卫生组织(WHO)2004/2016 分级系统被推荐使用,但其他系统,如 WHO1973 和 WHO1999 仍被广泛使用。最近,提出了一种混合(三级)系统,将 WHO2004/2016 高级别(HG)分为 HG/级别 2(G2)和 HG/G3,同时保持低级别。我们评估了 HG/G3 和 HG/G2 的预后性能。分析了 3 个独立队列的 9712 例原发性(首次诊断)Ta-T1 膀胱肿瘤。采用累积发生率函数和 Cox 回归模型分析进展时间。哈雷尔 C 指数用于评估判别能力。多变量分析显示,HG/G3 的进展时间明显短于 HG/G2(队列 1:风险比[HR] = 1.92;队列 2:HR = 2.51,队列 3:HR = 1.69)。相应的 5 年进展风险分别为 HG/G3 为 18%、20%和 18%,HG/G2 为 7.3%、7.5%和 9.3%。使用混合分级的 Cox 模型比使用 WHO2004/2016 的模型表现更好(所有队列;p < 0.001)。对于三个队列,WHO2004/2016 的 C 指数分别为 0.69、0.62 和 0.75,而混合分级的 C 指数分别为 0.74、0.68 和 0.78。将 HG 类别细分为 HG/G2 和 HG/G3 可分层进展时间,并支持采用混合分级系统对 Ta/T1 膀胱癌进行分级的建议。